Key result
Elevated serum H-FABP (>6.08 ng/ml) during the convalescent stage of acute myocardial infarction predicted an increased risk of long-term all-cause mortality (HR 1.91) compared to lower levels.
Why the study?
Does elevated serum H-FABP in the convalescent stage predict long-term mortality and readmission for HF in post-AMI patients?
Observational (n=1,283)
Yes
Does elevated serum H-FABP in the convalescent stage predict long-term mortality and readmission for HF in post-AMI patients?
Hazard Ratio: 1.91 (95% CI 1.03–3.51)
Absolute Event Rate: 18.3% vs 3.8%
p-value: p=0.039
Elevated serum H-FABP during the convalescent stage of AMI is a useful biomarker for predicting long-term mortality and heart failure readmission.
Convalescent H-FABP elevation was associated with higher post-AMI mortality; leaves open its incremental value for risk stratification in prospective studies.
BACKGROUND: Little is known about the prognostic significance of elevated serum heart-type fatty acid-binding protein (H-FABP) in post-acute myocardial infarction (post-AMI) patients. METHODS AND RESULTS: A total of 1,283 post-AMI patients with available serum samples collected in the convalescent stage were studied. During a median follow-up period of 1,785 days, 176 patients (14%) had adverse events (all-cause mortality, n=81; non-fatal MI, n=44; readmission for heart failure [HF], n=51). Patients were divided into 2 groups according to a serum H-FABP level of 6.08ng/ml, which was determined to be the optimal cut-off for discriminating all-cause mortality based on the maximum value of the area under the receiver operating characteristic curve. Patients with elevated H-FABP (>6.08ng/ml, n=224) had a significantly higher incidence of death (18.3% vs. 3.8%, P<0.001) and readmission for HF (10.3% vs. 2.6%, P<0.001), but not of non-fatal MI (4.5% vs. 3.2%, P=0.187), compared to those with H-FABP <6.08ng/ml. Multivariate Cox regression analysis indicated that elevated serum H-FABP was associated with an increased risk of mortality (hazard ratio [HR], 1.91; 95% confidence interval [CI]: 1.03-3.51, P=0.039) and readmission for HF (HR, 2.49; 95% CI: 1.15-5.39, P=0.020). CONCLUSIONS: Elevated serum H-FABP during the convalescent stage of AMI predicted long-term mortality and readmission for HF after survival discharge in the post-AMI patients.
No takes yet. Share an insight, caveat, or question.
Matsumoto et al. (2013) conducted an observational in Post-acute myocardial infarction (n=1,283). Elevated serum H-FABP (>6.08 ng/ml) vs. H-FABP ≤6.08 ng/ml was evaluated on All-cause mortality (HR 1.91, 95% CI 1.03-3.51, p=0.039). Elevated serum H-FABP (>6.08 ng/ml) during the convalescent stage of acute myocardial infarction predicted an increased risk of long-term all-cause mortality (HR 1.91) compared to lower levels.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: